Sai Life Sciences IPO Details
| IPO Issue Open Date: | 11 December 2024 |
| IPO Issue Close Date: | 13 December 2024 |
| IPO Issue Price Band: | ₹522 to ₹549 Per Share |
| Face Value: | ₹10 Per Equity Share |
| IPO Issue Size: | ₹3,042.62 Crores | 55,421,123 shares |
| Fresh Issue: | ₹950.00 Crores | 17,304,189 shares |
| Offer for Sale: | ₹[.] Crores |
| Issue Type: | Book Built Issue |
| IPO Listing At: | BSE & NSE |
| IPO Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| Employee Discount: | ₹[.] per share |
Sai Life Sciences IPO Prospectus:
Checkout the Sai Life Sciences IPO Prospectus of DRHP and RHP file.
Checkout the Sai Life Sciences IPO Prospectus of DRHP and RHP file.
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
Sai Life Sciences IPO Dates Timeline
| Issue Open Date: | 11 December 2024 |
| Issue Close Date: | 13 December 2024 |
| Basis of Allotment Date: | 16 December 2024 |
| Refunds Initiation: | 17 December 2024 |
| Shares Credit in Demat: | 17 December 2024 |
| IPO Listing Date Detail: | 18 December 2024 |
Sai Life Sciences IPO Market Lot
| Application | Lot Size, Shares and Price Details |
| Retail (Min) | 1 lots and 27 shares = ₹14,823 |
| Retail (Max) | 13 lots and 351 shares = ₹192,699 |
| S-HNI (Min) | 14 lots and 378 shares = ₹207,522 |
| B-HNI Minimum | 68 lots and 1,836 shares = ₹1,007,964 |
Sai Life Sciences IPO GMP*
| GMP Date | GMP Today | Subject to Sauda | Kostak | Expected Gain |
| 13 Dec | ₹25 | ₹500 | ₹- | 5% |
| 12 Dec | ₹40 | ₹700 | ₹- | 7% |
| 11 Dec | ₹30 | ₹549 | ₹500 | 5% |
| 10 Dec | ₹40 | ₹800 | ₹- | 7% |
| 9 Dec | ₹42 | ₹- | ₹- | 8% |
| 8 Dec | ₹- | ₹- | ₹- | -5% |
Check Live GMP
About Sai Life Sciences
Founded in January 1999, Sai Life Sciences Limited works with large creative pharma and biotech companies and provides services across drug discovery, development, and manufacturing of small molecule new chemical entities (NCE). Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO). The business addresses important healthcare issues by applying its scientific expertise. They want to significantly impact healthcare in the future by creating medications to treat diseases that are currently incurable. Whether it is a small client, a large biotech company, or a global pharmaceutical company, their services can be customized according to the customer’s needs making them adaptable and unstoppable. From fiscal year 2022 to 2024, they are surpassing their rivals in CRDMO in terms of revenue CAGR (Compound Annual Growth Rate) and EBITDA CAGR. Over the previous 24 years, they have consistently provided a broad range of NCE development programs to its clients. The three main areas where they have provided outstanding value to their clientele are quality, price, and response.
Sai Life Sciences IPO Strengths
- One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing
- CDMO platform with a diverse mix of commercial and under-development molecules
- Long-standing relationship with a diverse base of existing and new customers
- Experienced management team and Board supported by a qualified scientific talent pool
- Strategic business investments with improving profitability metrics
Objects of the IPO Issue
- To be updated soon
Sai Life Sciences Company Financial Report
The company reported revenue of ₹1,494.27 crores in 2024 against ₹1,245.11 crores in 2023. The company reported a profit of ₹82.81 crores in 2024 against a loss of ₹9.99 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹897.74 | ₹888.05 | ₹6.23 | ₹2,164.23 |
| 2023 | ₹1,245.11 | ₹1,228.70 | ₹9.99 | ₹2,186.65 |
| 2024 | ₹1,494.27 | ₹1,385.04 | ₹82.81 | ₹2,275.14 |
| September 2024 | ₹693.35 | ₹656.09 | ₹28.01 | ₹2,476.78 |
Sai Life Sciences IPO Valuation – Key Performance Indicator
KPI as of March 31, 2024.
| KPI | Values |
| ROE: | 8.49% |
| ROCE: | 10.26% |
| EBITDA Margin: | 20.48% |
| PAT Margin: | 5.65% |
| Debt to equity ratio: | 0.75 |
| Earning Per Share (EPS): | ₹4.57 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 8.50% |
| Net Asset Value (NAV): | ₹53.83 |
Peer Group Comparison
The below peer comparison table’s data are showing as per the DRHP and RHP.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Divi’s Laboratories Limited | 60.27 | 103.04 | 11.79% | 511.21 | 7,845.00 Cr. |
| Suven Pharmaceuticals Limited | 11.80 | 109.37 | 14.64% | 94.04 | 1,051.35 Cr. |
| Syngene International Limited | 12.71 | 73.59 | 11.98% | 105.91 | 3,488.60 Cr. |
Sai Life Sciences IPO Registrar
Link Intime India Private Ltd
Telephone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Sai Life Sciences IPO Lead Manager
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
- Morgan Stanley India Company Pvt Ltd
- Iifl Securities Ltd
Sai Life Sciences IPO allotment status noq on Link Intime website. Click on Link Intime IPO weblink to get allotment status.
Promoters of Sai Life Sciences
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
Company Address
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/